Investigators in a late-stage study of a new lung cancer drug owned by Eli Lilly and Bristol-Myers Squibb have slammed the brakes on enrolling new patients after monitors detected a risk of blood clots among new and recently enrolled subjects. But patients who have already received two cycles of necitumumab in combination with Alimta and cisplatin appear to have a lower risk of clots and may choose to continue the therapy. Another late-stage trial of the drug in combination with Gemzar and cisplatin is continuing. Lilly release